All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

perampanel 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
antagonists of the ionotropic non-NMDA (N-methyl-D-aspartate) glutamate receptors (Namely the AMPA (amino-hydroxymethyl-isoxazole-propionic acid) and/or KA (kainite antagonist) receptors)	4684	380917-97-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: perampanel hydrate perampanel fycompa E2007 E-2007	a non-competitive AMPA glutamate receptor antagonist indicated as adjunctive therapy for the treatment of seizures Molecular weight: 349.39 Formula: C23H15N3O CLOGP: 3.87 LIPINSKI: 0 HAC: 4 HDO: 0 TPSA: 56.99 ALOGS: -4.80 ROTB: 3 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
8	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution)	1.36 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.10 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.05 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	183 hours	Lombardo F, Berellini G, Obach RS
BA (Bioavailability)	1 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,DDR1,EIF2AK3,ERBB2,GRK2,ITK,MAPK10,MAPK7,MAPK9,MAPKAPK2,MET,PDK4,PIK3CB,PRKDC,SIK2,SIK3	21
kinase-selectivity-class	AXL,PDK4	2
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
Jan. 23, 2020	PMDA	Eisai Co., Ltd.
Oct. 22, 2012	FDA	EISAI INC
July 23, 2012	EMA	EISAI GMBH

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple-drug resistance	701.17	36.39	154	6906	7622	90613765
Aggression	478.42	36.39	146	6914	26522	90594865
Seizure	439.89	36.39	221	6839	152408	90468979
Status epilepticus	419.57	36.39	122	6938	18752	90602635
Drug ineffective	333.25	36.39	466	6594	1383832	89237555
Irritability	226.34	36.39	90	6970	35572	90585815
Drug resistance	211.35	36.39	82	6978	30367	90591020
Suicidal ideation	186.21	36.39	98	6962	73757	90547630
Somnolence	163.55	36.39	133	6927	208951	90412436
Drug interaction	148.40	36.39	142	6918	276311	90345076
Anticonvulsant drug level increased	143.13	36.39	32	7028	1704	90619683
Off label use	121.83	36.39	265	6795	1101987	89519400
Suicide attempt	114.63	36.39	72	6988	75327	90546060
Psychotic disorder	112.92	36.39	53	7007	31177	90590210
Epilepsy	106.51	36.39	71	6989	82135	90539252
Abnormal behaviour	105.94	36.39	46	7014	22582	90598805
Agitation	104.32	36.39	65	6995	67033	90554354
Intentional overdose	98.02	36.39	71	6989	93763	90527624
Generalised tonic-clonic seizure	95.56	36.39	49	7011	34854	90586533
Drug ineffective for unapproved indication	94.71	36.39	61	6999	66583	90554804
Cerebral salt-wasting syndrome	85.86	36.39	15	7045	217	90621170
Altered state of consciousness	85.54	36.39	44	7016	31488	90589899
Petit mal epilepsy	79.68	36.39	25	7035	4933	90616454
Dizziness	71.91	36.39	148	6912	589136	90032251
Ataxia	69.48	36.39	32	7028	18010	90603377
Anger	67.85	36.39	29	7031	13691	90607696
Cognitive disorder	66.77	36.39	50	7010	69357	90552030
Myoclonic epilepsy	66.43	36.39	17	7043	1610	90619777
Mood altered	64.75	36.39	30	7030	17114	90604273
Partial seizures	62.83	36.39	23	7037	7237	90614150
Pain	62.14	36.39	4	7056	996337	89625050
Rebound effect	57.09	36.39	23	7037	9361	90612026
Atonic seizures	56.24	36.39	13	7047	803	90620584
Hallucination	55.74	36.39	44	7016	65915	90555472
Abortion spontaneous	54.35	36.39	40	7020	54016	90567371
Lipids abnormal	49.98	36.39	10	7050	310	90621077
Seizure cluster	48.03	36.39	10	7050	379	90621008
Arthralgia	40.98	36.39	6	7054	778516	89842871
Dyspnoea	39.61	36.39	10	7050	880945	89740442
Drug withdrawal convulsions	39.12	36.39	11	7049	1489	90619898
Psychomotor hyperactivity	38.00	36.39	19	7041	12794	90608593
Behaviour disorder	37.58	36.39	14	7046	4621	90616766

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Aggression	573.32	32.55	225	6322	43938	42570850
Multiple-drug resistance	423.92	32.55	116	6431	7206	42607582
Seizure	343.62	32.55	219	6328	120342	42494446
Status epilepticus	341.49	32.55	117	6430	15461	42599327
Drug ineffective	234.34	32.55	374	6173	629823	41984965
Epilepsy	188.13	32.55	88	6459	26083	42588705
Suicide attempt	167.21	32.55	98	6449	46002	42568786
Irritability	161.19	32.55	81	6466	28047	42586741
Somnolence	151.52	32.55	144	6403	140961	42473827
Anger	109.91	32.55	49	6498	12969	42601819
Excessive eye blinking	86.34	32.55	20	6527	623	42614165
Intentional overdose	84.37	32.55	67	6480	51389	42563399
Anticonvulsant drug level above therapeutic	84.29	32.55	20	6527	693	42614095
Partial seizures	83.25	32.55	32	6515	5827	42608961
Psychotic disorder	77.62	32.55	51	6496	29157	42585631
Tonic convulsion	76.37	32.55	22	6525	1637	42613151
Off label use	75.38	32.55	241	6306	638094	41976694
Pneumonia aspiration	75.31	32.55	62	6485	50016	42564772
Generalised tonic-clonic seizure	74.86	32.55	48	6499	26331	42588457
Petit mal epilepsy	74.37	32.55	26	6521	3624	42611164
Ataxia	73.86	32.55	40	6507	16085	42598703
Homicidal ideation	73.05	32.55	24	6523	2770	42612018
Suicidal ideation	62.91	32.55	55	6492	48106	42566682
Gaze palsy	60.61	32.55	19	6528	1886	42612902
Agitation	58.31	32.55	60	6487	64254	42550534
Focal dyscognitive seizures	56.74	32.55	17	6530	1450	42613338
Posture abnormal	55.38	32.55	19	6528	2502	42612286
Drug interaction	54.74	32.55	124	6423	266875	42347913
Sudden unexplained death in epilepsy	53.07	32.55	13	6534	516	42614272
Hyperammonaemia	51.99	32.55	25	6522	7841	42606947
Behaviour disorder	51.47	32.55	24	6523	7030	42607758
Drug withdrawal convulsions	49.58	32.55	15	6532	1323	42613465
Abnormal behaviour	48.88	32.55	37	6510	26414	42588374
Physical assault	43.85	32.55	13	6534	1069	42613719
Altered state of consciousness	43.48	32.55	36	6511	29223	42585565
Haematuria traumatic	42.46	32.55	10	6537	335	42614453
Intensive care unit acquired weakness	41.72	32.55	13	6534	1265	42613523
Postictal paralysis	41.58	32.55	10	6537	367	42614421
Dyspnoea	41.06	32.55	9	6538	442612	42172176
Cognitive disorder	40.58	32.55	37	6510	34135	42580653
Muscle contracture	40.24	32.55	13	6534	1422	42613366
Anticonvulsant drug level increased	38.51	32.55	13	6534	1630	42613158
Seizure cluster	38.41	32.55	9	6538	295	42614493
Drug level decreased	38.18	32.55	22	6525	9955	42604833
Dysarthria	34.01	32.55	36	6511	39771	42575017
Quadriparesis	33.96	32.55	13	6534	2337	42612451

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Multiple-drug resistance	996.66	29.96	243	12315	12992	110563749
Aggression	922.84	29.96	319	12239	58891	110517850
Seizure	663.36	29.96	373	12185	220812	110355929
Status epilepticus	625.63	29.96	204	12354	31367	110545374
Drug ineffective	468.20	29.96	703	11855	1519837	109056904
Somnolence	327.25	29.96	270	12288	297179	110279562
Irritability	311.39	29.96	137	12421	47672	110529069
Suicide attempt	247.20	29.96	151	12407	103243	110473498
Epilepsy	246.39	29.96	149	12409	100060	110476681
Suicidal ideation	196.31	29.96	126	12432	93811	110482930
Off label use	195.76	29.96	484	12074	1499701	109077040
Drug resistance	184.38	29.96	101	12457	56273	110520468
Petit mal epilepsy	183.23	29.96	57	12501	7490	110569251
Drug interaction	180.29	29.96	251	12307	499932	110076809
Intentional overdose	168.08	29.96	131	12427	132370	110444371
Agitation	154.82	29.96	117	12441	112934	110463807
Generalised tonic-clonic seizure	151.79	29.96	88	12470	54592	110522149
Anger	145.13	29.96	61	12497	18946	110557795
Abnormal behaviour	133.32	29.96	72	12486	38967	110537774
Ataxia	127.06	29.96	64	12494	30044	110546697
Psychotic disorder	125.73	29.96	76	12482	50861	110525880
Anticonvulsant drug level increased	124.53	29.96	34	12524	2824	110573917
Partial seizures	123.41	29.96	47	12511	11302	110565439
Altered state of consciousness	112.22	29.96	74	12484	57552	110519189
Seizure cluster	98.00	29.96	22	12536	811	110575930
Behaviour disorder	97.91	29.96	38	12520	9609	110567132
Tonic convulsion	95.15	29.96	28	12530	3046	110573695
Excessive eye blinking	89.70	29.96	24	12534	1846	110574895
Drug ineffective for unapproved indication	89.70	29.96	82	12476	102756	110473985
Anticonvulsant drug level above therapeutic	88.91	29.96	22	12536	1240	110575501
Pneumonia aspiration	81.24	29.96	70	12488	81163	110495578
Focal dyscognitive seizures	80.69	29.96	26	12532	3823	110572918
Pain	79.99	29.96	8	12550	954947	109621794
Hyperammonaemia	78.62	29.96	36	12522	13696	110563045
Sudden unexplained death in epilepsy	76.80	29.96	18	12540	805	110575936
Cerebral salt-wasting syndrome	76.41	29.96	15	12543	284	110576457
Cognitive disorder	74.79	29.96	69	12489	87442	110489299
Dyspnoea	71.25	29.96	19	12539	1106853	109469888
Drug withdrawal convulsions	70.11	29.96	21	12537	2428	110574313
Postictal paralysis	65.48	29.96	15	12543	606	110576135
Drug level decreased	62.72	29.96	34	12524	18514	110558227
Dizziness	62.15	29.96	197	12361	697996	109878745
Atonic seizures	61.02	29.96	16	12542	1138	110575603
Gaze palsy	59.31	29.96	20	12538	3387	110573354
Arthralgia	59.21	29.96	9	12549	779623	109797118
Myoclonic epilepsy	55.69	29.96	18	12540	2673	110574068
Hostility	55.65	29.96	18	12540	2678	110574063
Posture abnormal	54.14	29.96	20	12538	4418	110572323
Intensive care unit acquired weakness	53.84	29.96	17	12541	2342	110574399
Prescribed underdose	53.00	29.96	50	12508	65124	110511617
Mood altered	50.42	29.96	31	12527	21344	110555397
Homicidal ideation	50.42	29.96	18	12540	3609	110573132
Haematuria traumatic	50.14	29.96	11	12547	364	110576377
Gait disturbance	49.34	29.96	102	12456	278106	110298635
Vagal nerve stimulator implantation	48.68	29.96	10	12548	240	110576501
Physical assault	46.77	29.96	14	12544	1614	110575127
Product administered to patient of inappropriate age	45.79	29.96	21	12537	8015	110568726
Malaise	42.26	29.96	12	12546	671807	109904934
Abdominal pain	41.09	29.96	5	12553	512984	110063757
Partial seizures with secondary generalisation	41.08	29.96	11	12547	848	110575893
Hyperammonaemic encephalopathy	40	29.96	17	12541	5417	110571324
Hallucination, auditory	39.84	29.96	29	12529	26368	110550373
Hallucination	39.48	29.96	53	12505	101379	110475362
Muscle contracture	39.28	29.96	14	12544	2794	110573947
Pruritus	39.23	29.96	9	12549	581551	109995190
Lipids abnormal	38.65	29.96	10	12548	675	110576066
Psychomotor hyperactivity	36.94	29.96	25	12533	20252	110556489
Drug reaction with eosinophilia and systemic symptoms	36.80	29.96	46	12512	82049	110494692
Intellectual disability	35.96	29.96	12	12546	1967	110574774
Disturbance in attention	34.85	29.96	39	12519	61956	110514785
Electroencephalogram abnormal	34.76	29.96	16	12542	6157	110570584
Dysarthria	34.35	29.96	45	12513	84076	110492665
Myoclonus	34.12	29.96	29	12529	32969	110543772
Overdose	33.81	29.96	79	12479	233715	110343026
Rebound effect	33.72	29.96	21	12537	14785	110561956
Abdominal discomfort	33.69	29.96	3	12555	393855	110182886
Delusion	33.38	29.96	25	12533	23730	110553011
Psychomotor skills impaired	32.71	29.96	16	12542	7042	110569699
Diarrhoea	32.11	29.96	50	12508	1139455	109437286
Change in seizure presentation	32.09	29.96	9	12549	825	110575916
Pain in extremity	31.94	29.96	8	12550	487110	110089631
Chest pain	31.83	29.96	3	12555	376372	110200369
Hypernatraemia	30.16	29.96	21	12537	17812	110558929

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N03AX22	NERVOUS SYSTEM ANTIEPILEPTICS ANTIEPILEPTICS Other antiepileptics
FDA MoA	N0000020016	AMPA Receptor Antagonists
FDA MoA	N0000182141	Cytochrome P450 3A4 Inhibitors
FDA EPC	N0000186106	Noncompetitive AMPA Glutamate Receptor Antagonist
FDA MoA	N0000187062	Cytochrome P450 2C8 Inhibitors
FDA MoA	N0000191273	UGT2B7 Inhibitors
FDA MoA	N0000191278	UGT1A9 Inhibitors
CHEBI has role	CHEBI:35469	antidepressant
CHEBI has role	CHEBI:35476	antipsychotic agent
CHEBI has role	CHEBI:35623	anticonvulsant
CHEBI has role	CHEBI:48407	antiparkinson drug
CHEBI has role	CHEBI:71014	AMPA receptor antagonist

Related Drugs by ATC class:

N03AX Other antiepileptics 18 drugs

beclamidebrivaracetamcannabidiolcarisbamatecenobamatefelbamatefenfluramineganaxolonelacosamidelamotriginelevetiracetamphenacemide show all 18 →

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Secondarily generalized seizures	indication	20544001
Partial seizure	indication	29753000
Idiopathic generalized epilepsy	indication	36803009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.89	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
0.5MG/ML	PERAMPANEL	MSN	A218152	July 11, 2025	RX	SUSPENSION	ORAL	June 14, 2026	PATENT CHALLENGE

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Glutamate receptor ionotropic AMPA	Ion channel	P42261 P42262 P42263 P48058	GRIA1_HUMAN GRIA2_HUMAN GRIA3_HUMAN GRIA4_HUMAN	ANTAGONIST	IC50	6.61		CHEMBL	CHEMBL

External reference:

ID	Source
D08964	KEGG_DRUG
4032964	VUID
N0000189940	NUI
4032964	VANDF
CHEBI:71013	CHEBI
CHEMBL1214124	ChEMBL_ID
C551441	MESH_SUPPLEMENTAL_RECORD_UI
7050	IUPHAR_LIGAND_ID
8834	INN_ID
DB08883	DRUGBANK_ID
H821664NPK	UNII
1356552	RXNORM
192918	MMSL
28817	MMSL
395327	MMSL
d07904	MMSL
014644	NDDF
703127006	SNOMEDCT_US
703728005	SNOMEDCT_US
C2698764	UMLSCUI
6ZP	PDB_CHEM_ID
9924495	PUBCHEM_CID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Perampanel	HUMAN PRESCRIPTION DRUG LABEL	1	0480-7062	TABLET, FILM COATED	2 mg	ORAL	ANDA	30 sections
Perampanel	HUMAN PRESCRIPTION DRUG LABEL	1	0480-7063	TABLET, FILM COATED	4 mg	ORAL	ANDA	30 sections
Perampanel	HUMAN PRESCRIPTION DRUG LABEL	1	0480-7065	TABLET, FILM COATED	6 mg	ORAL	ANDA	30 sections
Perampanel	HUMAN PRESCRIPTION DRUG LABEL	1	0480-7066	TABLET, FILM COATED	8 mg	ORAL	ANDA	30 sections
Perampanel	HUMAN PRESCRIPTION DRUG LABEL	1	0480-7067	TABLET, FILM COATED	10 mg	ORAL	ANDA	30 sections
Perampanel	HUMAN PRESCRIPTION DRUG LABEL	1	0480-7068	TABLET, FILM COATED	12 mg	ORAL	ANDA	30 sections
Perampanel	HUMAN PRESCRIPTION DRUG LABEL	1	51672-4204	TABLET, FILM COATED	2 mg	ORAL	ANDA	36 sections
Perampanel	HUMAN PRESCRIPTION DRUG LABEL	1	51672-4205	TABLET, FILM COATED	4 mg	ORAL	ANDA	36 sections
Perampanel	HUMAN PRESCRIPTION DRUG LABEL	1	51672-4206	TABLET, FILM COATED	6 mg	ORAL	ANDA	36 sections
Perampanel	HUMAN PRESCRIPTION DRUG LABEL	1	51672-4207	TABLET, FILM COATED	8 mg	ORAL	ANDA	36 sections
Perampanel	HUMAN PRESCRIPTION DRUG LABEL	1	51672-4208	TABLET, FILM COATED	10 mg	ORAL	ANDA	36 sections
Perampanel	HUMAN PRESCRIPTION DRUG LABEL	1	51672-4209	TABLET, FILM COATED	12 mg	ORAL	ANDA	36 sections
PERAMPANEL	HUMAN PRESCRIPTION DRUG LABEL	1	51672-4256	SUSPENSION	0.50 mg	ORAL	ANDA	38 sections
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	62856-272	TABLET	2 mg	ORAL	NDA	38 sections
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	62856-274	TABLET	4 mg	ORAL	NDA	38 sections
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	62856-276	TABLET	6 mg	ORAL	NDA	38 sections
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	62856-278	TABLET	8 mg	ORAL	NDA	38 sections
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	62856-280	TABLET	10 mg	ORAL	NDA	38 sections
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	62856-282	TABLET	12 mg	ORAL	NDA	38 sections
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	62856-290	SUSPENSION	0.50 mg	ORAL	NDA	38 sections
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	69616-272	TABLET	2 mg	ORAL	NDA	21 sections
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	69616-274	TABLET	4 mg	ORAL	NDA	21 sections
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	69616-276	TABLET	6 mg	ORAL	NDA	21 sections
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	69616-278	TABLET	8 mg	ORAL	NDA	21 sections
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	69616-280	TABLET	10 mg	ORAL	NDA	21 sections
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	69616-282	TABLET	12 mg	ORAL	NDA	21 sections
Fycompa	HUMAN PRESCRIPTION DRUG LABEL	1	69616-290	SUSPENSION	0.50 mg	ORAL	NDA	21 sections
PERAMPANEL	Human Prescription Drug Label	1	72205-071	SUSPENSION	0.50 mg	ORAL	ANDA	30 sections
Perampanel	Human Prescription Drug Label	1	72205-221	TABLET, FILM COATED	2 mg	ORAL	ANDA	29 sections
Perampanel	Human Prescription Drug Label	1	72205-222	TABLET, FILM COATED	4 mg	ORAL	ANDA	29 sections